Pair of Novo deals within Flagship framework among many ahead of JPM

Novo’s pair of metabolic deals, a platform agreement between Roche and MOMA, and a licensing arrangement giving start-up Avenzo a cancer program were among a spate of deals announced Thursday ahead of next week’s J.P. Morgan Healthcare Conference.

Working within a deal framework announced in May 2022 by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Flagship Pioneering, the Danish pharma struck deals with Flagship portfolio compaines Omega Therapeutics Inc. (NASDAQ:OMGA) and Cellarity Inc. to develop programs for metabolic disease...